Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is emerging as a notable player in the biopharmaceutical industry, having transitioned from a development-stage company to one with commercial revenue. The company's FDA-approved immunotherapy, LYMPHIR (denileukin diftitox-cxdl), has generated $5.6 million in net product revenue during the first six months of fiscal 2026, following its commercial launch in December 2025. This milestone underscores the company's ability to execute on its commercialization strategy and capture market share in the oncology space.
LYMPHIR is approved for the treatment of adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin. The drug's mechanism as an engineered fusion protein targeting IL-2 receptors is designed to offer a targeted approach for patients with limited options. Since its launch, LYMPHIR has achieved nearly 100% payer coverage of commercial lives, and 83% of targeted accounts have either achieved formulary inclusion or are under active review. Additionally, the company announced an initial shipment to Europe in April 2026, indicating expansion beyond the U.S. market.
Beyond its approved indication, Citius is exploring LYMPHIR's potential in combination with other therapies. Investigator-initiated studies have evaluated LYMPHIR with pembrolizumab in recurrent or refractory gynecologic cancers and prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, suggesting possible broader applications that could address significant unmet needs in oncology.
Citius's pipeline also includes Mino-Lok, a late-stage antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients. Mino-Lok met the primary and secondary endpoints in its pivotal Phase 3 trial, and it has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. The company believes Mino-Lok could generate worldwide sales of approximately $1.8 billion, addressing a critical need as there are currently no FDA-approved therapies specifically for salvaging infected catheters.
Another promising candidate is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for hemorrhoid symptom relief. With approximately 10 million people in the U.S. reporting hemorrhoid symptoms annually, and no FDA-approved prescription products specifically for this indication, Halo-Lido could become the first of its kind if approved. The company completed a Phase 2b study in 2023 and has engaged with the FDA on next steps.
Citius is also developing a stem cell platform using induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. Interim results from a proof-of-concept sheep model showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance, warranting further studies with larger sample sizes.
The company's leadership brings extensive experience in pharmaceutical development and commercialization. Leonard Mazur, Co-Founder, CEO, and Chairman, has five decades of industry experience, while Myron Holubiak, Co-Founder and Executive Vice Chairman, previously served as president of Roche Laboratories. This expertise positions Citius to navigate the complexities of drug development and market access.
With LYMPHIR generating commercial revenue and a robust pipeline, Citius Pharmaceuticals is poised for potential growth. The combination of an FDA-approved product, late-stage candidates with significant market opportunities, and a diversified portfolio across critical care and oncology offers multiple pathways for value creation. As the company continues to advance its programs, it remains focused on addressing unmet medical needs and delivering differentiated therapies to patients.
